Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Aβ levels

Neurobiology of Aging

Volumn 29, Issue 2, 2008, Pages 210-221

  Hellstrom Lindahl E ^a   Ravid, R ^b   Nordberg, A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NETHERLANDS BRAIN BANK   (Netherlands)

Author keywords

Aging; Alzheimer's disease; Amyloid peptide; Human brain; Neprilysin; Synaptophysin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; SYNAPTOPHYSIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; POSTMORTEM CHANGES; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC;

EID: 37549012213     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.10.010     Document Type: Article

References (66)

1. Apelt J., Ach K., and Schliebs R. Aging-related down-regulation of neprilysin, a putative b-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by astroglial upregulation in the vicinity of b-amyloid plaques. Neurosci. Lett. 339 (2003) 183-186
2. Akiyama H., Kondo H., Ikeda K., Kato M., and McGeer P.L. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid β-protein (Aβ) deposition. Brain Res. 902 (2001) 277-281
3. Braak H., and Braak E. Neuropathological stageing of Alzheimer's-related changes. Acta Neuropathol. 82 (1991) 239-259
4. Caccamo A., Oddo S., Sugarman M.C., Akbari Y., and La Ferla F.M. Age- and region-dependent alterations in Aβ degrading enzymes: implications for Aβ-induced disorders. Neurobiol. Aging 26 (2005) 645-654
5. Carpentier M., Robitaille Y., DesGroseilles L., Boileau G., and Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 6 (2002) 849-856
6. Carson J.A., and Turner A.J. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J. Neurochem. 81 (2001) 1-8
7. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
8. Davies P., Katzman R., and Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature 288 (1980) 279-280
9. Eckman E.A., and Eckman C.B. Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33 (2005) 1101-1105
10. Evin G., and Weidemann A. Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides 23 (2002) 1285-1297
11. Fukami S., Watanabe K., Iwata N., Haraoka J., Lu B., Gerard N.P., Gerard C., Fraser P., Westaway D., St. George-Hyslop P., and Saido T. Ab-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Ab pathology. Neurosci. Res. 43 (2002) 39-56
12. Fukumoto H., Rosene D., Moss M.B., Raju S., Hyman B.T., and Irizzarry M.C. β-Secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 164 (2004) 719-725
13. Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R., and Ihara Y. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152 (1998) 1633-1640
14. Guan Z.-Z., Nordberg A., Mousavi M., Rinne J.O., and Hellström-Lindahl E. Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. Brain Res. 956 (2002) 358-366
15. Hama E., Shirorani K., Masumot H., Sekine-Aiazawa Y., Aizawa H., and Saido T.M. Clearance of extracellular and cell-associated amyloid beta peptide through viral expression of neprilysin in primary neurons. J. Biochem. (Tokyo) 130 (2001) 721-726
16. Hellström-Lindahl E., Zhang X., and Nordberg A. Expression of nicotinic receptor subunits mRNAs in lymphocytes from normal and Alzheimer patients. Alzheimer's Res. 3 (1997) 29-36
17. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., and Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Mol. Brain Res. 66 (1999) 94-103
18. Hellström-Lindahl E., Court J., Keverne J., Svedberg M., Lee M., Marutle A., Thomas A., Perry E., Bednar I., and Nordberg A. Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci. 19 (2004) 2703-2710
19. Hellström-Lindahl E., Mousavi M., Ravid R., and Nordberg A. Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients. Neurobiol. Disease 15 (2004) 351-360
20. Higuchi M., Iwata N., and Saido T.C. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim. Biophys. Acta 1751 (2005) 60-67
21. Huang J., Guan H., Booze R.M., Eckman C., and Hersh L.B. Estrogen regulates neprilysin activity in rat brain. Neurosci. Lett. 367 (2004) 85-87
22. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., and Irizarry M.C. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62 (2004) 925-931
23. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St. George-Hyslop P.H., Mirra S.S., and Mori H. Aβ 1-40 but not Aβ 1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748 (1997) 250-252
24. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.-J., and Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science 292 (2001) 1550-1552
25. Iwata N., Takaki Y., Fukami S., Tsubuki S., and Saido T.C. Region-specific reduction of Aβ degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70 (2002) 493-500
26. Iwata N., Mizukami H., Shirotani K., Muramatsu S., Lu B., Gerard N.P., Gerard C., Ozawa K., and Saido T.O. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-β peptide in mouse brain. J. Neurosci. 24 (2004) 991-998
27. Kanemitsu H., Tomiyama T., and Mori H. Human neprilysin is capable of degrading amyloid b peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 350 (2003) 113-116
28. Kar S., Slowikowski P.M., Westaway D., and Mount H.T.J. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J. Psychiatry Neurosci. 29 (2004) 427-441
29. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M., and Selkoe D.J. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
30. Lu T., Pan Y., Kao S.Y., Li C., Kohane I., Chan J., and Yankner B.A. Gene regulation and DNA damage in the aging human brain. Nature 429 (2004) 883-891
31. Lue L.-F., Kuo Y.-M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
32. Mann D.M., Iwatsubo T., Pickering-Brown S.M., Owen F., Saido T.C., and Perry R.H. Preferential deposition of amyloid protein (Aβ) in the form of Aβ 40 in Alzheimers's disease is associated with gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 221 (1997) 81-84
33. Marr R.A., Guan H., Rockenstein E., Kindy M., Gage F.H., Verma I., Masliah E., and Hersh L.B. Neprilysin regulates amyloid β peptide levels. J. Mol. Neurosci. 22 (2004) 5-11
34. Mc Khann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of department of health and human services task forces on Alzheimer's disease. Neurology 34 (1984) 939-944
35. Mohajeri M.H., Wollmer M.A., and Nitsch R. Aβ 42-induced increase in neprilyin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277 (2002) 35460-35465
36. Mohajeri M.H., Kuehnle K., Li H., Poirier R., Tracy J., and Nitsch R. Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. FEBS Lett. 562 (2004) 16-21
37. Mousavi M., Hellström-Lindahl E., Guan Z.-Z., Shan K.-R., Ravid R., and Nordberg A. Protein and mRNA level of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. Neuroscience 122 (2003) 515-520
38. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., and Ihara Y. Effect of apolipoprotein E allele ε4 on the initial phase of amyloid B-protein accumulation in the human brain. Am. J. Pathol. 157 (2000) 2093-2099
39. Näslund J., Haroutunian V., Mohs R., Davis K.L., Grengaard P., and Buxbaum J.D. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
40. SWE). J. Neurochem. 81 (2002) 655-658
41. Pardossi-Piquard R., Petit A., Kawarai T., Sunyach C., Alves da Costa C., Vincent B., Ring S., Daadamio L., Shen J., Müller U., St. George Hyslop P., and Checler F. Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of β APP and APLP. Neuron 46 (2005) 541-554
42. Pardossi-Piquard R., Dunys J., Yu G., St. George-Hyslop P., Alves da Costa C., and Checler F. Neprilysin activity and expression are controlled by nicastrin. J. Neurochem. 97 (2006) 1052-1056
43. Parvathy S., Davies P., Haroutunian V., Purohit D.P., Davis K.L., Mohs R.C., Park H., Moran T.M., Chan J.Y., and Buxbaum J.D. Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch. Neurol. 58 (2001) 2025-2032
44. Petanceska S.S., Nagy V., Frail D., and Gandy S. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Exp. Gerontol. 35 (2000) 1317-1325
45. Piccini A., Russo C., Gliozzi A., Relin A., Vitali A., Borghi R., Giliberto L., Armirotti A., Dárrigo C., Bachi A., Cattaneo A., Canale C., Torassa S., Saido T.C., Markesbery W., Gambetti P., and Tabaton M. β-Amyloid is different in normal aging and in Alzheimer's disease. J. Biol. Chem. 280 (2005) 34186-34192
46. Price J.L., and Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45 (1999) 358-368
47. Qui W.Q., Ye Z., Kholodenko D., Seubert P., and Selkoe D.J. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other non-neuronal cells. J. Biol. Chem. 272 (1997) 6641-6646
48. Ravid R., Swaab D.F., Kamphorst W., and Salehi A. Brain banking in aging and dementia research-the Amsterdam experience. In: Fisher A., Yorshida M., and Hanin I. (Eds). Progress in Alzheimer's and Parkinson's Disease (1998), Plenum Press, New York 277-286
49. Reisberg B., Ferris S.H., Del Leon M.J., and Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychol. 139 (1982) 1136-1139
50. Roques B.P., Noble F., Daug V., Fournie-Zaluski M.C., and Beaumony A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacolgy. Pharmacol. Rev. 45 (1993) 87-146
51. Russo R., Borghi R., Markesberry W., Tabaton M., and Piccini A. Neprilysin decreases uniformly in Alzheimer's disease and in normal aging. FEBS 579 (2005) 6027-6030
52. Saito T., Iwata N., Tsubuki S., Takaki Y., Takamo J., Huang S.-M., Suemoto T., Higuchi M., and Saido T. Somatostatin regulates brain amylod B peptide Aβ 42 through modulation of proteolytic degradation. Nat. Med. 11 (2005) 434-439
53. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
54. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
55. Shinall H., Suk E., and Hersh L.B. Susceptibility of amyloid β peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 44 (2005) 15345-15350
56. Thai D.R., Rüb U., Orantes M., and Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58 (2002) 1791-1800
57. Turner A.J., Isaac R.E., and Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23 (2001) 261-269
58. Vardy E.R.L.C., Catto A.J., and Hooper N.M. Proteolytic mechanism in amyloid-β metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 1 (2005) 462-472
59. Walker L.C., Pahnke J., Madauss M., Vogelgesang S., Pahnke A., Herbst E.W., Stausske D., Walther R., Kessler C., and Warzok R.W. Apolipoprotein E4 promotes the early deposition of Aβ 42 and the Aβ40 in the elderly. Acta Neuropathol. 100 (2000) 36-42
60. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid β protein inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
61. Wang D.-S., Iwata N., Hama E., Saido T., and Diclson D.W. Oxidized neprilysin in aging and Alzheimer's disease. Biochem. Biophys. Res. Commun. 310 (2003) 236-241
62. Wang D.-S., Lipton R.B., Katz M.J., Davies P., Buschke H., Kuslansky G., Vergese J., Younkin S.G., Eckman C., and Dickson D.W. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J. Neuropathol. Exp. Neurol. 64 (2005) 378-385
63. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anakov R., Yan F., Silverstein C., and Husemann J. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. 9 (2003) 453-457
64. Yasojima K., Akiyama H., McGeer E.G., and McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 297 (2001) 97-100
65. Yasojima K., McGeer E.G., and McGeer P.L. Relationship between amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919 (2001) 115-121
66. Zhu X., Lee H.G., Casadesus G., Avila J., Drew K., Perry G., and Smith M.A. Oxidative imbalance in Alzheimer's disease. Mol. Neurobiol. 31 (2005) 205-217